Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000668093 | SCV000792641 | pathogenic | Deficiency of alpha-mannosidase | 2017-07-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000668093 | SCV001220761 | pathogenic | Deficiency of alpha-mannosidase | 2025-01-01 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ser890*) in the MAN2B1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MAN2B1 are known to be pathogenic (PMID: 9915946, 22161967). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with mannosidosis (PMID: 22161967). ClinVar contains an entry for this variant (Variation ID: 552770). For these reasons, this variant has been classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000668093 | SCV001364014 | pathogenic | Deficiency of alpha-mannosidase | 2019-05-02 | criteria provided, single submitter | clinical testing | Variant summary: MAN2B1 c.2669C>G (p.Ser890X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 245278 control chromosomes (gnomAD). c.2669C>G has been reported in the literature in compound heterozygote individuals affected with Alpha-Mannosidosis (Rise Stensland_2012). These data indicate that the variant is likely associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. A ClinVar submission from a clinical diagnostic laboratory (evaluation after 2014) cites the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Genome- |
RCV000668093 | SCV002014518 | pathogenic | Deficiency of alpha-mannosidase | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000668093 | SCV004191908 | pathogenic | Deficiency of alpha-mannosidase | 2023-11-27 | criteria provided, single submitter | clinical testing |